ENDRA Competitors

Stocks . USA . 
Stock . ENDRA Life Sciences
NDRA Stock  USD 3.80  0.20  5.00%   
ENDRA Life Sciences competes with Applied DNA, Venus Concept, Bone Biologics, ISpecimen, and Movano; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing ENDRA Life competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of ENDRA Life to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out ENDRA Life Correlation with its peers.

ENDRA Life vs Bio Green Correlation

Good diversification

The correlation between ENDRA Life Sciences and BGMS is -0.05 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding ENDRA Life Sciences and BGMS in the same portfolio, assuming nothing else is changed.

Moving against ENDRA Stock

  0.61BA BoeingPairCorr
  0.53GNTX GentexPairCorr
  0.51CVX Chevron CorpPairCorr
  0.5AA Alcoa CorpPairCorr
  0.47INTC Intel Aggressive PushPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.193.8010.96
Details
Intrinsic
Valuation
LowRealHigh
0.183.6510.81
Details
Naive
Forecast
LowNextHigh
0.073.7310.89
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
3.924.475.02
Details

ENDRA Life Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ENDRA Life and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of ENDRA and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ENDRA Life Sciences does not affect the price movement of the other competitor.

High positive correlations

GCTK
+ 0.92
BNBX
DHAI
+ 0.74
BNBX
ISPC
+ 0.67
BNBX
BGMS
+ 0.66
GCTK
DHAI
+ 0.63
GCTK
BGMS
+ 0.61
BNBX
  

High negative correlations

HSCS
- 0.52
GCTK
HSCS
- 0.45
BNBX
ISPC
- 0.41
NAOV
GCTK
- 0.38
NAOV
NAOV
- 0.36
BNBX
DHAI
- 0.31
NAOV

Risk-Adjusted Indicators

There is a big difference between ENDRA Stock performing well and ENDRA Life Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ENDRA Life's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BNBX  5.02 (1.44) 0.00 (0.55) 0.00 
 0.00 
 11.06 
(11.39)
 46.29 
VERO  15.35  4.65  0.33 (2.85) 10.60 
(23.81)
 10.24 
(14.29)
 516.97 
BBLG  3.29 (0.41) 0.00 (0.31) 0.00 
 0.00 
 6.84 
(8.38)
 22.82 
NAOV  4.73 (0.36) 0.00  0.78  0.00 
 0.00 
 10.43 
(9.07)
 36.24 
ISPC  5.69 (0.92) 0.00 (0.25) 0.00 
 0.00 
 11.54 
(11.76)
 37.80 
MOVE  11.43  3.87  0.52  1.18  6.26 
(16.17)
 16.73 
(11.74)
 164.71 
GCTK  4.84 (1.66) 0.00 (1.21) 0.00 
 0.00 
 8.36 
(10.85)
 56.93 
HSCS  4.25  0.17  0.02 (1.91) 5.04 
(5.01)
 11.07 
(6.48)
 26.18 
DHAI  75.30  34.58  0.72 (2.26) 28.15 
(131.83)
 320.00 
(76.19)
 976.19 
BGMS  4.81 (0.56) 0.00 (0.69) 0.00 
 0.00 
 11.89 
(8.79)
 25.45 

ENDRA Life Competitive Analysis

The better you understand ENDRA Life competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ENDRA Life's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ENDRA Life's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NDRA BNBX VERO BBLG NAOV ISPC MOVE GCTK HSCS DHAI
 5.00 
 3.80 
ENDRA
 1.55 
 1.31 
Applied
 10.24 
 1.40 
Venus
 0.61 
 1.63 
Bone
 1.95 
 4.02 
NanoVibronix
 2.86 
 0.34 
ISpecimen
 10.17 
 17.13 
Movano
 15.86 
 1.91 
GlucoTrack
 0.93 
 3.20 
Heart
 400.00 
 0.01 
DIH
Market Volatility
(90 Days Market Risk)
Very risky
Abnormally volatile
Out of control
Dangerous
Very risky
Out of control
Very risky
Dangerous
Very risky
Out of control
Market Performance
(90 Days Performance)
Weakest
Weakest
Mild
Weakest
Weakest
Weakest
Good
Weakest
Mild
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
High
Strong
Risky
Hazard
Risky
Low
Risky
Risky
Moderate
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Hold
Strong Buy
Not Available
Not Available
Not Available
Not Available
Strong Buy
Strong Sell
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Not Rated
Strong Sell
Cautious Hold
Cautious Hold
Strong Sell
Strong Sell
Current Ratio
9.64
N/A
2.74
80.11
3.07
13.37
6.78
4.52
3.53
N/A
Net Asset
4.45 M
4.44 M
68.18 M
3.86 M
3.63 M
9.35 M
11.32 M
5.93 M
4.22 M
26.75 M
Profit Margin
N/A
N/A
-0.93
N/A
-2.52
N/A
N/A
N/A
N/A
-0.14
EBITDA
(10.77 M)
(13.33 M)
(36.04 M)
107.16 K
(3.69 M)
(12.73 M)
(24.06 M)
(21.98 M)
(8.14 M)
(7.11 M)
Current Valuation
4.4 M
N/A
30.6 M
(3.03 M)
910.11 K
713.35 K
18.56 M
(2.5 M)
9.16 M
12.95 M
Price To Book
27.22
N/A
0.9
0.5
0.11
1.05
3.2
0.75
2.45
3.03
Operating Margin
N/A
N/A
-0.69
N/A
-3.11
-26.55
-32.39
N/A
-857.13
-0.22
Retained Earnings
(103.44 M)
(379.16 M)
(308.9 M)
(85.02 M)
(69.8 M)
(71.86 M)
(148.11 M)
(132.45 M)
(76.13 M)
(43.89 M)
Current Asset
1.27 M
N/A
N/A
1.07 M
1.78 M
N/A
138.64 M
N/A
N/A
N/A
Beta
-0.3
N/A
-0.038
0.41
2.06
1.84
0.79
0.33
2.54
-0.093
Number Of Employees
21
26
292
2
31
24
32
11
15
178
Shares Outstanding
1.5 M
N/A
1.86 M
1.8 M
1.09 M
9.77 M
909.49 K
910.69 K
3.18 M
2.09 M
Cash Flow From Operations
(7.4 M)
(12.52 M)
(11.07 M)
(4.12 M)
(2.52 M)
(8.26 M)
(22.53 M)
(12.49 M)
(7.41 M)
(4.14 M)
Total Debt
584.42 K
2.5 M
43.03 M
377.71 K
116 K
312.17 K
186 K
267 K
2.99 M
11.96 M
Return On Equity
-2.36
N/A
-7.95
-0.8
-0.31
-2.96
-3.99
-14.91
-2.2
N/A
Return On Asset
-1.02
N/A
-0.32
-0.49
-0.2
-0.75
-0.96
-2.26
-0.75
-0.0824
Number Of Shares Shorted
49.38 K
N/A
172.61 K
40.74 K
22.85 K
311.31 K
25.44 K
31.89 K
30.53 K
19.07 K
Book Value Per Share
0.22
N/A
1.44
3.35
42.0
0.31
-2.04
3.06
1.36
-21.97
Current Liabilities
619.6 K
N/A
N/A
2.16 M
297 K
N/A
40.62 M
N/A
N/A
N/A
Total Asset
4.45 M
4.44 M
68.18 M
3.86 M
3.63 M
9.35 M
11.32 M
5.93 M
4.22 M
26.75 M
Debt To Equity
0.046
N/A
7.84
N/A
0.008
0.14
0.025
0.06
0.41
N/A
Short Ratio
2.87
N/A
0.05
0.05
0.83
0.13
0.44
1.03
0.4
0.02
Target Price
30.0
N/A
10.6
22.25
10.5
3.0
300.0
N/A
10.6
N/A
Shares Owned By Institutions
12.1
N/A
15.6
0.84
0.52
3.48
9.15
0.77
5.7
N/A
Market Capitalization
5.69 M
N/A
2.36 M
2.94 M
4.69 M
3.52 M
15.58 M
1.74 M
10.17 M
2.09 K
Price To Earning
-0.93
N/A
N/A
-15.45
-5.34
0.78
39.53
N/A
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
-0.09
N/A
N/A
N/A
N/A
Price To Sales
N/A
N/A
0.0401
N/A
1.75
1.05
31.16
N/A
1173.18
N/A
Net Income
(11.51 M)
(15.16 M)
(46.97 M)
(4.11 M)
(3.71 M)
(12.5 M)
(23.73 M)
(22.6 M)
(8.77 M)
(8.68 M)
Earnings Per Share
18.54
N/A
-45.26
-2.33
-51.81
-8.49
-19.76
-1067.32
-6.56
-6.07
Shares Owned By Insiders
36.25
N/A
0.82
0.03
0.76
0.67
26.91
5.68
5.12
27.9
Revenue
N/A
2.14 M
64.83 M
N/A
2.56 M
9.29 M
1.01 M
N/A
4.35 K
62.86 M
Working Capital
2.83 M
(225.49 K)
18.23 M
3.48 M
609 K
(2.18 M)
6.95 M
4.49 M
(1.53 M)
(4.61 M)
Cash And Equivalents
11.28 M
N/A
6.78 M
5.45 M
3.94 M
23.69 M
21.3 M
3.85 M
4.27 M
N/A
Cash Per Share
0.18
N/A
0.1
0.53
0.14
2.67
0.65
0.25
0.52
N/A
Gross Profit
N/A
N/A
37.89 M
N/A
806 K
722.54 K
(1.35 M)
(20 K)
5.02 K
32.21 M
Day Typical Price
3.88
1.32
1.38
1.65
4.09
0.35
17.69
2.0
3.26
0.0037
Accumulation Distribution
0.0617
2852.61
141579.0
1542.4
0.0565
10175.35
0.11
0.13
661.79
1205.6
Market Facilitation Index
0.25
0.0
N/A
0.0
0.24
N/A
2.07
0.29
0.0
0.0
Daily Balance Of Power
(0.80)
0.1667
0.7222
(0.12)
(0.33)
(0.33)
(0.94)
(1.24)
(0.17)
1.0
Period Momentum Indicator
(0.20)
0.02
0.13
(0.01)
(0.08)
(0.01)
(1.94)
(0.36)
(0.03)
0.004
Rate Of Daily Change
0.95
1.02
1.1
0.99
0.98
0.97
0.9
0.84
0.99
5.0
Day Median Price
3.93
1.32
1.37
1.66
4.13
0.36
17.97
2.05
3.29
0.003
Price Action Indicator
(0.23)
N/A
0.095
(0.04)
(0.15)
(0.02)
(1.81)
(0.32)
(0.10)
0.004
Relative Strength Index
42.07
34.59
47.32
44.14
42.03
43.18
65.68
26.76
52.62
19.76
Coefficient Of Variation
(3,822)
(555.18)
1264.22
(1,309)
(1,852)
(1,032)
672.87
(454.74)
3179.51
458.67
Mean Deviation
5.17
5.02
15.35
3.29
4.73
5.69
11.43
4.84
4.25
75.3
Jensen Alpha
(0.25)
(1.44)
4.65
(0.41)
(0.36)
(0.92)
3.87
(1.66)
0.1732
34.58
Total Risk Alpha
(0.64)
(1.79)
0.9563
(0.64)
(0.81)
(1.26)
2.33
(2.05)
(0.19)
24.18
Sortino Ratio
N/A
N/A
0.327
N/A
N/A
N/A
0.5163
N/A
0.023
0.7208
Downside Variance
N/A
N/A
191.63
N/A
N/A
N/A
59.54
N/A
28.81
2204.13
Standard Deviation
7.16
7.33
57.93
4.52
6.87
7.86
27.18
7.24
5.7
155.48
Kurtosis
1.44
4.12
61.0
0.5582
2.56
2.42
23.65
6.6
1.35
18.76
Potential Upside
12.24
11.06
10.24
6.84
10.43
11.54
16.73
8.36
11.07
320.0
Treynor Ratio
(0.17)
(0.55)
(2.85)
(0.31)
0.7767
(0.25)
1.18
(1.21)
(1.91)
(2.26)
Maximum Drawdown
38.62
46.29
516.97
22.82
36.24
37.8
164.71
56.93
26.18
976.19
Variance
51.28
53.76
3356.36
20.44
47.23
61.75
738.81
52.44
32.44
24174.62
Market Risk Adjusted Performance
(0.16)
(0.54)
(2.84)
(0.30)
0.7867
(0.24)
1.19
(1.20)
(1.90)
(2.25)
Risk Adjusted Performance
(0.01)
(0.12)
0.0679
(0.05)
(0.03)
(0.06)
0.1187
(0.15)
0.0318
0.1698
Skewness
(0.25)
(0.51)
7.65
0.1037
0.7884
0.9474
4.78
(0.66)
0.0639
4.14
Semi Deviation
N/A
N/A
10.6
N/A
N/A
N/A
6.26
N/A
5.04
28.15
Information Ratio
(0.03)
(0.19)
0.0781
(0.09)
(0.06)
(0.10)
0.1466
(0.23)
0.0217
0.2177
Value At Risk
(11.36)
(11.39)
(14.29)
(8.38)
(9.07)
(11.76)
(11.74)
(10.85)
(6.48)
(76.19)
Expected Short fall
N/A
N/A
(23.81)
N/A
N/A
N/A
(16.17)
N/A
(5.01)
(131.83)
Downside Deviation
N/A
N/A
13.84
N/A
N/A
N/A
7.72
N/A
5.37
46.95
Semi Variance
N/A
N/A
112.36
N/A
N/A
N/A
39.19
N/A
25.42
792.38

ENDRA Life Competition Performance Charts

Five steps to successful analysis of ENDRA Life Competition

ENDRA Life's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ENDRA Life Sciences in relation to its competition. ENDRA Life's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of ENDRA Life in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ENDRA Life's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ENDRA Life Sciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your ENDRA Life position

In addition to having ENDRA Life in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Financials ETFs Thematic Idea Now

Financials ETFs
Financials ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Financials ETFs theme has 54 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether ENDRA Life Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ENDRA Life's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Endra Life Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Endra Life Sciences Stock:
How To Invest In ENDRA
Details
Is ENDRA Stock a good investment?
Details
What is ENDRA Life's Net Worth?
Details
Top Sectors
View
Check out ENDRA Life Correlation with its peers.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ENDRA Life. Anticipated expansion of ENDRA directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ENDRA Life assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding ENDRA Life Sciences requires distinguishing between market price and book value, where the latter reflects ENDRA's accounting equity. The concept of intrinsic value—what ENDRA Life's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push ENDRA Life's price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between ENDRA Life's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ENDRA Life should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, ENDRA Life's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY